CROI 2010
CROI 2010: ART Intensification with Maraviroc (Selzentry) or Raltegravir (Isentress) May Improve Immune Activation and Inflammation
- Details
- Category: HIV Treatment
- Published on Tuesday, 16 March 2010 13:57
- Written by Liz Highleyman
The CCR5 antagonist maraviroc (Selzentry) was associated with reduced immune activation and inflammation in 3 studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. The integrase inhibitor raltegravir (Isentress) may also have some inflammation-dampening effect, but 3 recent studies produced mixed results.
CROI 2010: Inflammation and Immune Activation Linked to Increase Mortality Risk in People with HIV
- Details
- Category: HIV Basic Science
- Published on Tuesday, 16 March 2010 00:00
- Written by Liz Highleyman
Inflammation and excessive CD8 T-cell immune activation were independent predictors of increased risk of death both in a U.S. study and among HIV patients starting antiretroviral therapy (ART) in Uganda, according to 2 reports presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. While lower CD4 cell count may explain part of the association, inflammation itself was an independent predictor of mortality.
CROI 2010: IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Friday, 12 March 2010 12:48
- Written by Liz Highleyman
A human genetic variation previously shown to predict hepatitis C prognosis in people with HCV alone may play a similar role in HIV/HCV coinfected individuals, according to a set of studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. The IL28B non-risk genotype associated with both spontaneous HCV clearance and response to interferon-based hepatitis C treatment was less common among people of African descent, perhaps helping explain disparities in treatment outcomes.
CROI 2010: HIV/HBV and HIV/HCV Coinfected People with Impaired Liver Function and Inflammation Have Higher Risk of Non-AIDS Death
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 12 March 2010 12:57
- Written by Liz Highleyman
HIV positive study participants with hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection who had higher blood levels of biomarkers associated with impaired liver function and inflammation were more likely to die of non-AIDS-related causes, researchers with the SMART treatment interruption trial reported last month at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco.
CROI 2010: HIV Infection and HIV/HCV Coinfection Increased Risk of Strokes in Veterans Study
- Details
- Category: Cardiovascular Disease
- Published on Friday, 05 March 2010 12:57
- Written by Liz Highleyman
HIV positive veterans had about twice the risk of having a stroke as their HIV negative counterparts, and being coinfected with hepatitis C virus (HCV) further elevated the risk, but hepatitis C alone conferred an insignificant increase, according to a poster presented at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last month in San Francisco. The researchers suggested stroke death may have been underestimated in the past.
More Articles...
- CROI 2010: LEDGF/p75 Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication
- CROI 2010: ACTG 5202 Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads
- CROI 2010: Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Reduce Response
- CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
Web Design and Development by